This study focuses on individuals who are 40-80 years old and have been diagnosed with Parkinson's disease. The purpose of the study is to determine the safety and effectiveness of an investigational drug called CVL-751 (tavapadon) as a possible treatment for Parkinson's disease. Tavapadon works by targeting the dopamine system in the brain. At Cedars-Sinai, only participants who complete the trials of tavapadon CVL-751-PD-001 and CVL-751-PD-003 will be eligible. The study is divided into 3 time periods: a 58-week treatment period, a 10-day safety/withdrawal assessment period and a 20-day safety follow-up period. During each study period, participants will have one or more visits with their study doctor.
What is the full name of this clinical trial?
58-Week Open-label Trial of Tavapadon in Parkinson s Disease
Echo Tan, Elliot Hogg